Lung as a target for COVID-19: Mechanistic insights and probable candidate molecules for cure

J Infect Public Health. 2024 Apr;17(4):573-578. doi: 10.1016/j.jiph.2024.01.014. Epub 2024 Jan 24.

Abstract

Novel coronavirus (SARS nCoV2), belonging to the family coronaviridae, remains a dreadful pathogen affecting the respiratory tract and lungs. COVID-19 declared a global pandemic by WHO, has become a serious cause of concern for clinicians and researchers, who need to understand the significant biology and pathogenicity of this virus to design better treatment modalities. Existing antiretroviral drugs remain partially ineffective in critical subjects with associated co-morbidities. This review provides an insight into the molecular mechanisms by which SARS-CoV2 targets the lungs leading to ARDS in severe cases. This also addresses the possible drug targets and certain anti-inflammatory natural compounds that can be looked upon as promising adjuvant therapeutics for COVID-19.

Keywords: COVID-19; Inflammation; Lung; Natural compounds; SARS-CoV2.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • COVID-19*
  • Humans
  • Lung
  • RNA, Viral
  • SARS-CoV-2

Substances

  • RNA, Viral
  • Anti-Inflammatory Agents